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Platelets	are	critical	to	blood	clotting	and	represent	the	first	responders	to	blood	vessel	damage.		A	striking	feature	of	platelet	activation	
is	their	transition	from	the	discoid	resting	cell	to	the	stimulated	“spider”	that	first	attaches	to	the	damaged	site	and	then	to	the	“fried	
egg”	that	spreads	over	the	wounded	surface.		These	morphological	changes	are	thought	to	be	reliant	on	cytoskeletal	elements	such	
as	actin	filaments	and	microtubules.	 	While	much	is	know	about	how	actin	affects	platelet	responses	(and	Brett	confirmed	these	
effects),	less	is	know	about	the	role	of	microtubules.		Specifically,	are	microtubules	important	for	platelet	function?		Brett’s	data	begins	
to	address	this	question.		Using	microtubule	stabilizing	and	destabilizing	drugs,	he	showed	that	microtubule	assembly	had	no	role	in	
platelet	function.		Treatment	with	vinblastine	and	nocodazole	had	no	effect	on	shape	change,	aggregation,	or	secretion.		Microtubule	
disassembly	was	necessary	from	some	aspects	of	platelet	function,	because	treatment	with	paclitaxel	(a	microtubule	stabilizer)	inhibited	
aggregation	and	secretion,	but	not	shape	change.		Additional	studies	focused	on	the	role	of	the	cytoskeleton	in	activation	of	the	small	
GTP-binding	protein	Arf6.		Arf6	has	been	shown	to	be	a	key	control	element	during	aggregation	and	has	been	suggested	to	affect	
actin	cytoskeletal	changes	upon	platelet	activation.	Both	paclitaxel	and	latrunculin	A	(an	actin	depolymerizer)	treatment	blocked	Arf6	
activation	in	thrombin	and	convulxin-stimulated	platelets.		These	results	show	that	dynamic	changes	in	the	platelet	cytoskeleton	are	
required	for	function	and	suggest	a	feedback	mechanism	from	the	cytoskeleton	may	control	Arf6	activation.
Role of Cytoskeletal 
Dynamics in Platelet 
Arf6 Activation
Abstract 
Platelets	 undergo	morphological	 changes	 upon	
activation,	 such	 as	 shape	 change	 and	 aggrega-
tion.	These	changes	are	known	to	be	the	result	of	
actin	remodeling,	whereas	the	role	of	microtubule	
remodeling	has	been	controversial.	The	objective	
of	this	study	was	to	re-examine	the	role	of	actin	
and	microtubule	 dynamics	 in	platelet	 function.	
We	used	aggregometry	to	measure	the	effect	of	
cytoskeletal	inhibitors	on	platelet	shape	change,	
aggregation,	and	dense	core	release.	Microtubule	
assembly	was	found	to	have	no	role	 in	platelet	
function,	because	 treatment	with	vinblastine	or	
nocodazole	had	no	effect	on	shape	change,	ag-
gregation,	or	secretion.	Microtubule	disassembly	
was	necessary	for	some	aspects	of	platelet	func-
tion,	because	treatment	with	paclitaxel	inhibited	
aggregation	and	secretion,	but	not	shape	change.	
Actin	assembly	was	confirmed	to	be	an	essential	
event	 in	 platelet	 activation.	 We	 then	 assessed	
the	 role	 of	 microtubule	 disassembly	 and	 actin	
assembly	 in	 ADP-ribosylation	 factor	 6	 (Arf6)	
activation,	because	Arf6	is	a	key	signaling	com-
ponent	in	platelet	activation.	Using	GST-GGA3,	we	
monitored	Arf6-GTP	levels	over	time	in	paclitaxel	
and	latrunculin	A-treated	platelets.	Paclitaxel	and	
latrunculin	A	treatment	blocked	Arf6	activation	in	
thrombin	and	convulxin-stimulated	platelets,	re-
spectively.	These	results	suggest	that	microtubule	
disassembly	and	actin	assembly	are	important	for	
Arf6	activation	in	platelets.
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Introduction
Platelets	are	 responsible	 for	maintaining	 the	 integrity	
of	 the	vascular	 system.	They	 seal	 off	 vascular	 injury	
by	adhering	to	lesions,	aggregating,	and	secreting	their	
granule	 contents.	 These	 processes	 are	 all	 aspects	 of	
platelet	activation,	which	 is	 initiated	by	physiological	
agonists	generated	at	a	lesion	site	such	as	exposed	col-
lagen	(Barnes	et	al.,	1998)	and	locally	activated	thrombin	
(Brass,	2003).	
Resting	platelets	circulate	in	the	bloodstream	in	their	
native,	discoid	shape	and	undergo	a	rapid	shape	change	
upon	activation	of	various	surface	receptors.	This	shape	
change	is	the	result	of	cytoskeletal	remodeling.	The	role	
of	 actin	 filaments	 in	 cytoskeletal	 transformation	has	
been	well	characterized	(Hartwig,	2006;	Lefebvre	et	al.,	
1993;	Natarajan	et	al.,	2000;	Torti	et	al.,	1996;	White,	
1984;	Winokur	and	Hartwig,	1995),	whereas	the	role	of	
microtubules	is	still	a	subject	of	interest,	because	previ-
ous	studies	(Bouaziz	et	al.,	2007;	Cerecedo	et	al.,	2002;	
White	and	Rao,	1982;	White	and	Rao,	1983;	White	and	
Sauk,	1984)	have	yielded	conflicting	results.	
ADP-Ribosylation	Factor	6	(Arf6),	a	small	G	protein	
of	the	Ras	superfamily,	has	been	known	to	affect	cyto-
skeletal	dynamics	 in	eukaryotic	cells	 (Boshans	et	al.,	
2000;	Donaldson,	2003;	Donaldson	and	Honda,	2005;	
D’Souza-Schorey	and	Chavrier,	 2006;	Gillingham	and	
Munro,	2007;	Myers	and	Casanova,	2008;	Song	et	al.,	
1998)	and	platelets	(Choi	et	al.,	2006).	Recently,	it	was	
found	that	Arf6	behaves	unlike	the	other	small	GTPases	
in	platelets;	the	active	form,	Arf6-GTP,	is	present	in	rest-
ing	platelets	and	rapidly	decreases	upon	activation	with	
primary	agonists	(Choi	et	al.,	2006;	Karim	et	al.,	2008).	
The	decrease	was	shown	to	display	a	biphasic	profile;	
an	initial	decrease	through	primary	surface	receptors,	i.e,	
protease	activated	receptor	(PAR)	and	glycoprotein	VI	
(GPVI)	receptor,	and	a	secondary	phase	initiated	by	the	
outside-in	signaling	of	activated	αIIbβ3	integrins	(Kasirer-
Friede	et	al.,	2007;	Shattil,	1999)	during	the	later	stages	
of	platelet	activation	(Karim	et	al.,	2008).	
In	this	report,	I	have	re-investigated	the	physiologi-
cal	role	of	cytoskeletal	dynamics	in	platelet	activation.	In	
addition,	I	have	sought	to	determine	the	role	of	specific	
cytoskeletal	remodeling	events	 in	the	control	of	Arf6-
GTP	levels.	
Results and Discussion 
Role of microtubule remodeling in 
platelet function
Platelets	undergo	a	morphological	change,	mediated	by	
the	cytoskeleton,	upon	stimulation	with	primary	ago-
nists.	The	first	objective	of	this	study	was	to	determine	
the	role	of	microtubules,	if	any,	in	platelet	function.	To	
accomplish	this,	we	treated	platelets	with	microtubule	
inhibitors	known	to	disrupt	the	dynamic	instability	of	
microtubules.	By	inhibiting	specific	events	in	microtu-
bule	remodeling,	we	were	able	to	assess	their	importance	
in	platelet	function,	i.e.,	shape	change,	aggregation,	and	
dense	core	granule	release.	
We	assessed	the	role	of	microtubule	assembly	by	
treating	platelets	with	microtubule	 destabilizers,	 vin-
blastine	or	nocadozole,	prior	to	activation.	Each	drug	
binds	and	stabilizes	free	tubulin	dimers	to	prevent	their	
incorporation	into	microtubules.	Vinblastine	treatment	
had	no	effect	on	shape	change,	aggregation,	or	dense	
core	granule	secretion	in	thrombin	and	convulxin-stimu-
lated	platelets	(Figure	1:	A-C).	Nocodazole	treatment	also	
had	no	effect	on	any	aspect	of	platelet	function	(Figure	
2:	A-C).	Although	both	destabilizers	appeared	to	affect	
aggregation	at	low	concentrations,	they	were	unable	to	
display	a	dose-dependent	response.
Microtubule	 disassembly	 is	 thought	 to	 be	 the	
mechanism	of	remodeling	in	the	early	stages	of	platelet	
activation	(Hartwig,	2006).	To	assess	the	role	of	micro-
tubule	disassembly,	we	treated	platelets	with	paclitaxel,	
a	microtubule	stabilizer	that	prevents	disassembly,	prior	
to	activation.	Paclitaxel	treatment	had	no	effect	on	shape	
change,	but	aggregation	was	partially	inhibited,	at	higher	
Figure 1. Effect of vinblastine on platelet aggrega-
tion and dense core granule release. 
A,B) Washed platelets were pre-incubated with the indi-
cated concentration of vinblastine or equivalent volume 
of DMSO (vehicle) for 5 minutes prior to stimulation. 
Platelets were stimulated with (A) thrombin (0.3 U/mL) 
or (B) convulxin (0.1 µg/mL) and monitored for shape 
change and aggregation over 5 minutes. 
C) Washed platelets were pre-incubated with 25 
µL luciferin-luciferase (Chrono-Lume) and 2.5 µM vin-
blastine or equivalent volume of DMSO (vehicle) for 
5 minutes prior to stimulation. Thrombin (0.3 U/mL) 
was used to stimulate the platelet solution to monitor 
dense core granule ATP release. 
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concentrations,	in	convulxin-stimulated	platelets	(Figure	
3:	A,B).	Interestingly,	aggregation	was	unaffected	at	5-
fold	higher	concentrations	of	paclitaxel,	up	to	25	µM,	in	
thrombin-stimulated	platelets	(data	not	shown).	Dense	
core	granule	release	was	inhibited	at	low	concentrations	
of	 paclitaxel	 (Figure	 3C).	 Taken	 together,	 these	 data	
suggest	 that	microtubule	assembly	has	no	major	role	
in	platelet	function,	whereas	microtubule	disassembly	
may	play	a	role	in	platelet	aggregation	and	secretion,	
but	not	shape	change.	
Role of microtubule remodeling in Arf6 
activation
Because	we	observed	an	important	role	for	microtubule	
dynamics	 in	platelet	 function,	we	 sought	 to	 examine	
whether	microtubule	remodeling	is	necessary	for	Arf6	
activation	(decrease	of	Arf6-GTP).	Previous	studies	(Choi	
et	al.,	2006;	Karim	et	al.,	2008)	showed	that	Arf6-GTP	
decreases	upon	stimulation	with	primary	agonists	and	
that	the	decrease	in	Arf6-GTP	is	necessary	for	full	platelet	
activation.	We	monitored	Arf6-GTP	levels	in	vinblastine,	
nocodazole,	 or	 paclitaxel-treated	 platelets	 following	
stimulation	with	thrombin	or	convulxin.	
Vinblastine	 and	nocodazole	 treatment	 had	 little	
effect	on	Arf6	activation,	whereas	paclitaxel	treatment	
blocked	the	Arf6-GTP	decrease	(Figure	4A).	The	ability	
of	paclitaxel	to	disrupt	Arf6-GTP	levels	further	supports	
microtubule	disassembly	as	an	integral	event	in	platelet	
activation.	 Interestingly,	 the	 Arf6-GTP	 decrease	 was	
inhibited	by	paclitaxel	in	thrombin-stimulated	platelets,	
but	not	convulxin-stimulated	platelets	(Figure	4B);	this	
finding	is	most	likely	a	reflection	of	the	unique	signaling	
events	involved	in	the	PAR	and	GPVI	signaling	pathways,	
but	could	also	be	indicative	of	a	larger	role	for	microtu-
bule	disassembly	in	PAR-mediated	activation.	
One	interpretation	of	the	inhibition	of	the	Arf6-GTP	
decrease	by	paclitaxel	is	that	microtubule	disassembly	
is	a	necessary	and	upstream	event	of	Arf6	activation	
in	 PAR-mediated	 platelet	 activation.	 Because	Arf6	 is	
upstream	of	 the	 outside-in	 signaling	 of	 activated	 aIIa3	
integrins	(Choi	et	al.,	2006),	this	would	place	microtu-
bule	disassembly	upstream	of	aIIa3	integrin	activation	as	
well.	Although	paclitaxel	treatment	could	have	a	global	
effect	on	multiple	primary	signaling	events,	this	is	not	
likely	 because	Arf6	 activation	would	be	disrupted	 in	
both	PAR	and	GPVI-mediated	activation.	
Figure 2. Effect of nocodazole on platelet aggrega-
tion and dense core granule release. 
A,B) Washed platelets were pre-incubated with the indi-
cated concentration of nocodazole or equivalent volume 
of DMSO (vehicle) for 5 minutes prior to stimulation. 
Platelets were stimulated with (A) thrombin (0.3 U/mL) 
or (B) convulxin (0.1 µg/mL) and monitored for shape 
change and aggregation over 5 minutes. 
C) Washed platelets were pre-incubated with 25 
µL luciferin-luciferase (Chrono-Lume) and 5 µM no-
codazole or equivalent volume of DMSO (vehicle) for 5 
minutes prior to stimulation. Thrombin (0.3 U/mL) was 
used to stimulate the platelet solution to monitor dense 
core granule ATP release. 
Figure 3. Effect of paclitaxel on platelet aggregation 
and dense core granule release. 
A,B) Washed platelets were pre-incubated with the indi-
cated concentration of paclitaxel or equivalent volume 
of DMSO (vehicle) for 5 minutes prior to stimulation. 
Platelets were stimulated with (A) thrombin (0.3 U/mL) 
or (B) convulxin (0.1 µg/mL) and monitored for shape 
change and aggregation over 5 minutes. 
C) Washed platelets were pre-incubated with 25 
µL luciferin-luciferase (Chrono-Lume) and 1.25 µM 
paclitaxel or equivalent volume of DMSO (vehicle) for 
5 minutes prior to stimulation. Thrombin (0.3 U/mL) 
was used to stimulate the platelet solution to monitor 
dense core granule ATP release. 
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Because	 we	 established	 a	 role	 for	 microtubule	
disassembly	in	Arf6	activation,	we	further	defined	the	
relationship	by	monitoring	Arf6-GTP	levels	over	a	time	
course	in	paclitaxel-treated	platelets.	In	DMSO-treated	
platelets,	 thrombin	 stimulation	 induced	 an	Arf6-GTP	
decrease	that	was	maximal	(~70%	decrease	from	resting	
state)	in	fully	aggregated	platelets	(300	sec).	In	paclitaxel-
treated	platelets,	thrombin	stimulation	did	not	induce	
a	 similar	Arf6-GTP	decrease;	Arf6-GTP	 levels	 initially	
declined	(10	sec),	but	remained	at	a	similar	level	(~40%	
decrease)	for	the	remainder	of	the	time	course	(Figure	
5A).	Paclitaxel	treatment	did	not	affect	the	Arf6-GTP	de-
crease	at	any	time	point	in	convulxin-stimulated	platelets	
(Figure	5B).	These	data	support	a	role	for	microtubule	
disassembly	in	Arf6	activation,	which	may	be	upstream	
of	Arf6	in	PAR-mediated	platelet	activation.	
Role of actin assembly in platelet 
activation and aggregation
Actin	filaments	make	up	 the	majority	 of	 the	platelet	
cytoskeleton	and	are	 responsible	 for	 the	morphologi-
cal	changes	seen	in	platelet	activation	(Hartwig,	2006;	
Lefebvre	 et	 al.,	 1993;	Natarajan	 et	 al.,	 2000;	Torti	 et	
al.,	1996;	White,	1984;	Winokur	and	Hartwig,	1995).	
Aggregometry	was	used	to	re-examine	the	role	of	actin	
assembly	 in	 platelet	 activation	 and	 aggregation.	 We	
used	latrunculin	A,	an	actin	destabilizer	that	binds	and	
stabilizes	free	actin	monomers,	to	inhibit	actin	assembly.	
Latrunculin	A	treatment	blocked	platelet	shape	change	
at	 low	concentrations,	and	showed	a	dose-dependent	
inhibition	of	aggregation	(Figure	6).	These	data	confirm	
the	importance	of	actin	assembly	in	platelet	activation	
and	aggregation.
Figure 4. Effect of microtubule inhibitors on Arf6-
GTP levels. 
A, B) Washed platelets were pre-incubated with the 
indicated concentration of vinblastine, nocodazole, or 
paclitaxel for 5 minutes prior to stimulation. Platelets 
were stimulated with (A) thrombin (0.3 U/mL) or (B) 
convulxin (0.1 µg/mL) and allowed to aggregate for 5 
minutes. Platelets were lysed at the end of the aggrega-
tion reaction and the clarified supernatants were assayed 
for Arf6-GTP, using GST-GGA3. Arf6-GTP was identified 
using SDS-PAGE/Western blot analysis. The data points 
are normalized to the amount of Arf6-GTP in resting 
platelets (100%). 
Figure 5. Time course of Arf6-GTP in platelets pre-
incubated with paclitaxel. 
A, B) Washed platelets were pre-treated with 2.5 
µM paclitaxel for 5 minutes prior to stimulation. Plate-
lets were stimulated with (A) thrombin (0.3 U/ml) or 
(B) convulxin (0.1 µg/mL) and allowed to aggregate 
for the indicated times (10, 30, 60, 120, or 300 sec). 
Platelets were lysed at the indicated time points and 
the clarified supernatants were analyzed for Arf6-GTP, 
using GST-GGA3, and Arf6-Total. Arf6 was identified 
using SDS-PAGE/Western blot analysis. Data points are 
represented as a ratio of Arf6-GTP to Arf6-Total and are 
normalized to the Arf6-GTP/Arf6-Total ratio in resting 
platelets (100%). 
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Role of actin as-
sembly in Arf6 
activation
A	previous	study	(Choi	et	
al.,	2006)	has	shown	that	
isoform-specific	 inhibi-
tors	of	Arf6	disrupt	actin	
dynamics	in	platelets.	We	
sought	to	further	charac-
terize	this	relationship	by	
determining	whether	ac-
tin	assembly	is	upstream	
of	Arf6	by	treating	plate-
lets	 with	 latrunculin	 A	
and	monitoring	Arf6-GTP	
levels	 following	convulxin	stimulation.	Latrunculin	A	
treatment	caused	a	dose-dependent	block	of	Arf6	activa-
tion	(Figure	7A).	Using	the	lowest	concentration	of	la-
trunculin	A	shown	to	block	Arf6	activation,	we	examined	
a	time	course	of	Arf6-GTP	levels	in	convulxin-stimulated	
platelets.	Latrunculin	A	treatment	blocked	the	decrease	
in	Arf6-GTP	at	nearly	every	time	point	(Figure	7B).	
These	results	suggest	that	actin	assembly	may	be	
upstream	of	Arf6	activation	in	the	GPVI-mediated	sig-
naling	pathway.		Because	actin	remodeling	is	known	to	
play	a	role	in	the	inside-out	activation	of	aIIa3	integrins	
(Falet	et	al.,	2005),	the	effect	of	latrunculin	A	on	Arf6-
GTP	could	be	from	integrin-based	outside-in	signaling	
or	actin	remodeling	is	acting	both	upstream	and	down-
stream	of	Arf6	activation,	as	previously	proposed	(Choi	
et	al.,	2006).	Nonetheless,	these	data	support	a	role	for	
actin	assembly	in	Arf6	activation.	
Conclusion
In	this	report,	we	defined	a	role	for	integral	cytoskeletal	
remodeling	events	in	Arf6	activation.	Using	inhibitors,	
we	 established	 the	 cytoskeletal	 remodeling	 events	
necessary	for	full	platelet	function.	Paclitaxel	treatment	
inhibited	aggregation	and	dense	core	granule	release,	
supporting	a	role	for	microtubule	disassembly	in	platelet	
function.	Latrunculin	A	treatment	blocked	shape	change	
and	inhibited	aggregation,	confirming	the	role	of	actin	
assembly	in	platelet	activation	and	aggregation.	
We	 then	determined	 a	 role	 for	 these	 cytoskeletal	
remodeling	 events	 in	Arf6	 activation.	Both	paclitaxel	
and	 latrunculin	 A	 treatment	 disrupted	 Arf6	 activity,	
suggesting	 that	 microtubule	 disassembly	 and	 actin	
assembly,	 respectively,	 are	 necessary	 events	 for	 the	
Arf6-GTP	decrease	in	stimulated	platelets.	Microtubule	
disassembly	may	be	upstream	of	Arf6	activation	and	
actin	assembly	could	be	upstream	and	downstream	of	
Arf6	activation	in	PAR	and	GPVI-mediated	activation,	
respectively.	This	marks	the	first	report	to	link	specific	
cytoskeletal	 remodeling	 events	 to	 Arf6	 signaling	 in	
platelets.	
Figure 6. Effect of latrunculin A on platelet shape change and aggregation. 
Washed platelets were pre-incubated with the indicated concentration of latrunculin A or 
equivalent volume of DMSO (vehicle) for 5 minutes prior to stimulation. Platelets were 
stimulated with convulxin (0.1 µg/mL) and monitored for shape change and aggregation 
over 5 minutes. 
Figure 7. 
Effect of latrunculin A on Arf6-GTP levels. 
Washed platelets were pre-incubated with the indicated 
concentration of latrunculin A or equivalent volume 
of DMSO (vehicle) for 5 minutes prior to stimulation. 
Platelets were stimulated with convulxin (0.1 µg/mL) 
and monitored for shape change and aggregation for 
the indicated times [(A) 300 sec] or [(B) 10, 30, 60, 120, 
300, or 600 sec]. Following lysis at the indicated time 
points, clarified supernatants were assayed for Arf6-GTP, 
using GST-GGA3, and Arf6-Total. Arf6 was identified 
using SDS-PAGE/Western blot analysis. Data points are 
represented as a ratio of Arf6-GTP to Arf6-Total and are 
normalized to the Arf6-GTP/Arf6-Total ratio in resting 
platelets (100%). 
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